JX-1395
Jennerex product candidate, JX-1395, is engineered using a vaccinia strain backbone that is optimized for potency and tumor selectivity. Furthermore, JX-1395 includes enhancements for spread to distant tumors and for immunotargeting of lung, prostate and other solid tumors, including expression of GM-CSF to stimulate a systemic anti-tumor immune response. JX-1395 is currently in the preclinical development stage.
